ArticleAmerican journal of preventive medicine2026
Comorbidities Associated With Chronic Hepatitis C Among Medicaid Beneficiaries, 2016-2020.
Article in American journal of preventive medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionUnderstanding comorbidities of chronic hepatitis C is crucial for improving care for affected persons. The prevalence of comorbidities associated with chronic hepatitis C among Medicaid beneficiaries is reported.
methodsA descriptive retrospective cohort study was conducted using Centers for Medicare & Medicaid Services 2016-2021 data of Medicaid beneficiaries aged 18-64 years with a chronic hepatitis C diagnosis, not dually enrolled in Medicare, and with ≥12 months of continuous enrollment after diagnosis. The prevalence of comorbidity diagnoses (HIV, chlamydia, gonorrhea, syphilis, mental health disorders, substance use disorders, overdoses, and alcohol poisonings) was estimated within 12 months after the chronic hepatitis C diagnosis date. Results were stratified by younger (18-44 years) and older (45-64 years) age groups. Multivariable log-binomial regression was used to generate adjusted prevalence ratios for each comorbidity to compare between age groups.
resultsAmong enrolled Medicaid beneficiaries, 487,413 had diagnosed chronic hepatitis C. Those aged 18-44 years (n=198,086) were more likely to be female (54%) than those aged 45-64 years (40%; n=289,327). The highest prevalences of comorbidity diagnoses were any substance use disorder (53%) and any mental health disorder (50%). In adjusted models, beneficiaries aged 18-44 years were less likely to have an HIV diagnosis (adjusted prevalence ratio=0.56; 95% CI=0.43, 0.74) than those aged 45-64 years. Conversely, younger beneficiaries were more likely to be diagnosed with other comorbidities, including chlamydia (adjusted prevalence ratio=5.72; 95% CI=4.54, 7.19) and any overdose or alcohol poisoning (adjusted prevalence ratio=2.09; 95% CI=1.95, 2.24).
conclusionsApproximately half of the Medicaid beneficiaries with diagnosed chronic hepatitis C had a mental health disorder or a substance use disorder. Younger beneficiaries had higher prevalences of comorbidities than older beneficiaries, excluding HIV. Prioritizing and supporting evidence-based programs that provide comprehensive services for Medicaid beneficiaries with hepatitis C and comorbid diagnoses may help beneficiaries address multiple conditions more effectively.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.